SCHEDULE: Sabby Management Reveals 9.9% Stake in InMed Pharma

Sabby Management, Hal Mintz, and Sabby Volatility Warrant Master Fund, Ltd. have disclosed a 9.9% beneficial ownership stake in InMed Pharmaceuticals Inc.

Summary

• Sabby Management, LLC, Hal Mintz, and Sabby Volatility Warrant Master Fund, Ltd. have jointly reported beneficial ownership of 280,138 shares of InMed Pharmaceuticals Inc. Common Stock.
• This ownership represents 9.9% of the total outstanding shares of InMed Pharmaceuticals Inc.
• The reporting persons share both voting and dispositive power over all 280,138 shares.
• The securities were not acquired or held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

NA

Industry Context

This filing indicates significant institutional interest in InMed Pharmaceuticals Inc. by Sabby Management, a firm known for its investment strategies. Such disclosures can sometimes signal a vote of confidence or a strategic position being taken in the biotechnology or pharmaceutical sector, which often sees active institutional participation.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake (9.9%) by Sabby Management could be viewed positively, potentially signaling increased institutional confidence or interest in InMed Pharmaceuticals Inc. This could influence market perception and trading activity.

Key Dates

Keywords

InMed Pharmaceuticals, Sabby Management, Hal Mintz, Sabby Volatility Warrant Master Fund, Beneficial Ownership, Common Stock, SEC Filing, Schedule 13G, Institutional Ownership